There was evidence that the effect of SGLT2 inhibitors on total stroke varies by baseline eGFR (P = 0.01), with protection in the lowest eGFR (< 45 mL/min/1.73 m2) subgroup (HR = 0.50) [81]. The gene discussed is SLC5A2; the disease is stroke disorder.